Oncoinvent would like to extend an invitation to a presentation of the Q3 2019 results. The presentation will be held at 14:00 on Thursday 31. October 2019 in the company offices at Gullhaugsveien 7, Oslo, 2nd Floor.
To attend, please register with
The quarterly report will be made available on www.oncoinvent.com on the 31. October 2019
Organiser: Oncoinvent ASGullhaugsveien 7, Oslo
Oncoinvent ASA Gullhaugveien 7 0484 Oslo Norway
mansson@oncoinvent.com
Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.
Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.